Postoperative lomefloxacin 0.3% prophylaxis in strabismus surgery.
OBJECTIVE
To evaluate the efficacy of topical lomefloxacin 0.3% versus chloramphenicol 0.2% with polymyxin B 2500 U/ml in the treatment of patients after strabismus surgery.


METHODS
Seventy-nine consecutive patients who underwent strabismus surgery from April through October 2006 were randomized to receive topical lomefloxacin 0.3% (n = 45, 58 eyes) or chloramphenicol 0.2% with polymyxin B 2500 U/ml (n = 34, 40 eyes) postoperatively, in addition to topical dexamethasone 0.1% and diclophenac 0.1%. The groups were compared for clinical signs of local cellulitis and findings on conjunctival cultures.


RESULTS
From postoperative day 1 to day 28, rates of chemosis decreased from 96% to 9.5% in the lomefloxacin group and from 94% to zero in the chloramphenicol group; rates of hyperemia decreased from 100% to zero in both groups. Accordingly, rates of a cumulative clinical sign score (CCSS) decreased from 60% to zero in the lomefloxacin group and 50% to zero in the chloramphenicol group. Rates of positive bacterial cultures dropped from 59.6% preoperatively to 48.3% on day 14 in the lomefloxacin group and from 63% to 47% in the chloramphenicol group.


CONCLUSIONS
Topical lomefloxacin is a potent alternative to topical chloramphenicol eye drops after strabismus surgery for the control of pain, infection and discharge, chemosis, hyperemia, and conjunctival hemorrhage.
Pediatric Ophthalmology Unit, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel. msnir@clalit.org.il
Moshe
M
Snir
Murat
M
Hasanreisoglu
Ronit
R
Friling
Nitza
N
Goldenberg-Cohen
Rita
R
Ehrlich
Judith
J
Bagan
Ruth
R
Axer-Siegel
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D002701:Chloramphenicol / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006940:Hyperemia / Q000517:prevention & control; D007223:Infant; D008297:Male; D008875:Middle Aged; D009801:Oculomotor Muscles / Q000601:surgery; D010149:Postoperative Pain / Q000517:prevention & control; D011112:Polymyxin B / Q000008:administration & dosage / Q000627:therapeutic use; D011182:Postoperative Care; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D013285:Strabismus / Q000601:surgery*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002701:Chloramphenicol; D011112:Polymyxin B; C053091:lomefloxacin